PENNSYLVANIA, April 20 - (ii) as a percentage of the total company profits

realized in the United States that were derived from the

sale of the drug for each of the previous three years.

(4) The aggregate amount of all rebates that the

manufacturer provided to all payers, including, but not

limited to, insurers and pharmacy benefit managers, for the

sale of the drug within this Commonwealth for each of the

previous three years.

(5) A description of the manufacturer's patient

prescription assistance programs available in the United

States that include a drug under subsection (a), including,

but not limited to:

(i) The amount of financial assistance provided for

each of the previous three years.

(ii) The amount of financial assistance provided to

residents of this Commonwealth for each of the previous

three years.

(iii) The average per capita amount of assistance to

residents of this Commonwealth and the drugs for which

assistance was provided for each of the previous three

years.

(iv) The eligibility and benefit structure of the

patient prescription assistance programs, including

coupons.

(6) Payments or financial incentives, direct or

indirect, to hospitals, health care providers or physicians

located in this Commonwealth attributable to a drug under

subsection (a), including, but not limited to, speaking fees,

dinners, research, consulting, charitable donations, grants

or other incentives, discounts or rebates for each of the

20210SB0579PN0625 - 10 -

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30